KROS
MaterialsKeros Therapeutics Inc
$11.78+0.01 (+0.08%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving KROS Today?
No stock-specific AI insight has been generated for KROS yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$233M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume305K
Avg Volume (10D)—
Shares Outstanding19.8M
KROS News
20 articles- KROS 2026 Watchlist: 3 Catalysts That Could Reset SentimentYahoo Finance·Apr 20, 2026
- KROS Rinvatercept: What to Know Before DMD Phase II StartsYahoo Finance·Apr 20, 2026
- Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report?Yahoo Finance·Apr 3, 2026
- Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock?Yahoo Finance·Mar 31, 2026
- KROS: Is the Discount Book Value a Value Trap?Yahoo Finance·Mar 17, 2026
- KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026Yahoo Finance·Mar 17, 2026
- KROS Stock: What to Know About Rinvatercept in DMDYahoo Finance·Mar 17, 2026
- Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALSYahoo Finance·Mar 9, 2026
- Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific ConferenceYahoo Finance·Mar 9, 2026
- Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?Yahoo Finance·Mar 6, 2026
- Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 4, 2026
- Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 4, 2026
- Keros Therapeutics Touts Rinvatercept DMD Trial Start, Eyes ALS Phase II Talks at Oppenheimer ConferenceMarketbeat·Feb 28, 2026
- Keros Therapeutics Appoints Charles Newton to its Board of DirectorsYahoo Finance·Feb 26, 2026
- Keros Therapeutics Announces Participation at Upcoming Healthcare ConferencesYahoo Finance·Feb 18, 2026
- SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMDYahoo Finance·Jan 27, 2026
- Is KROS' KER-065 the Next Breakthrough in DMD Space?Yahoo Finance·Jan 26, 2026
- Ionis' Dawnzera Gets EU Approval for Hereditary AngioedemaYahoo Finance·Jan 22, 2026
- MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to KnowYahoo Finance·Jan 21, 2026
- Axsome Therapeutics Begins Phase III Study on AXS-14 for FibromyalgiaYahoo Finance·Jan 16, 2026
All 20 articles loaded
Price Data
Open$11.84
Previous Close$11.77
Day High$11.95
Day Low$11.58
52 Week High—
52 Week Low—
Fundamentals
Market Cap$233M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume305K
Avg Volume (10D)—
Shares Outstanding19.8M
About Keros Therapeutics Inc
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—